9月9日，作为全球唯一能够大规模量产短读长与长读长测序产品的高端制造商，华大智造(688114)发布 DNBSEQ系列最新款超高通量基因测序仪T7+。T7+可在24小时内交付超14Tb的测序数据，平均每10分 钟完成1例（每小时完成6例）、每年完成高达35000例的人全基因组测序，打破了高产与快速无法兼得 的困境，刷新了规模测序极速。 值得注意的是，华大智造基于长短读长技术可为用户提供以"全读长"（SEQ ALL）为目标的全流程工具 矩阵。T7+与全球单芯片通量最高的纳米孔长读长测序仪 CycloneSEQ G400-ER平台完美搭档。能够互 补协同，呈现完整的基因组图景。 T7+发布后，在华大智造CEO牟峰与总裁余德健的见证下，华大基因（300676）、吉因加、贝瑞科技、 美吉生物、欧易生物、派森诺、格致博雅共7家不同领域的用户代表与华大智造董事会秘书、副总裁彭 欢欢共同签署合作协议，成为T7+首批签约客户。 在PE150读长下，T7+可在24小时内完成超14Tb的数据产出，是全球日交付能力最强的超高通量基因测 序仪，平均每10分钟完成1例人全基因组测序（Whole Genome Sequencing，简称 ...

Core Insights - BGI Genomics launched the latest ultra-high-throughput sequencing instrument, DNBSEQ T7+, which can deliver over 14 terabases of sequencing data within 24 hours [1] - The device can complete one whole genome sequencing every 10 minutes, equating to six per hour, and up to 35,000 per year, addressing the challenge of balancing high output with speed [1] Company Highlights - The introduction of the DNBSEQ T7+ marks a significant advancement in sequencing technology, potentially enhancing BGI's competitive edge in the genomics market [1] - The ability to perform large-scale sequencing rapidly may attract more clients and increase market share for BGI Genomics [1] Industry Implications - The launch of the T7+ could set new standards for throughput and efficiency in the genomics industry, influencing competitors to innovate [1] - This advancement may lead to broader applications of genomic sequencing in research and clinical settings, driving growth in the overall genomics market [1]

Core Viewpoint - BGI Genomics (688114.SH) has launched the T7+ ultra-high-throughput gene sequencer, which is currently the world's strongest daily delivery capacity sequencer, capable of producing over 14 terabases of data in 24 hours [1] Group 1: Product Features - The T7+ can complete a whole genome sequencing (WGS) every 10 minutes, with an annual processing capacity of up to 35,000 WGS [1] - The T7+ offers high accuracy and cost-effective large-scale sequencing, complementing the CycloneSEQ G400-ER platform, which provides ultra-long read sequencing [1] Group 2: Market Availability - The T7+ is available for immediate sale in mainland China, with shipments to Hong Kong, Macau, Taiwan, and overseas regions expected to begin in Q4 2025 [1]

人民财讯9月9日电，记者获悉，华大智造(688114)发布超高通量测序仪T7+。超高通量测序仪T7+可在24 小时内交付超14Tb的测序数据，平均每10分钟完成1例、每年完成高达35000例的人全基因组测序，打 破了高产与快速无法兼得的困境，刷新了规模测序极速。 ...

证券日报网讯 9月8日晚间，华大智造发布公告称，公司2025年第三次临时股东大会于2025年9月8日召 开，审议通过了《关于公司及摘要的议案》等多项议案。 （文章来源：证券日报） ...

北京市嘉源律师事务所 关于深圳华大智造科技股份有限公司 2025 年第三次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 班 邮 甲 直源律师事务所 IA YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:深圳华大智造科技股份有限公司 北京市嘉源律师事务所 关于深圳华大智造科技股份有限公司 2025 年第三次临时股东大会的 法律意见书 嘉源(2025)-04-640 北京市嘉源律师事务所(以下简称"本所")接受深圳华大智造科技股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简 称"《公司法》")《上市公司股东会规则》(以下简称"《股东会规则》") 等现行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规") 以及《深圳华大智造科技股份有限公司章程》（以下简称"《公司章程》"）的 有关规定,指派本所律师对公司2025年第三次临时股东大会(以下简称"本次股 东大会"）进行见证,并依法出具本 ...

证券代码：688114 证券简称：华大智造 公告编号：2025-058 深圳华大智造科技股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 8 日 （二） 股东大会召开的地点：深圳市盐田区梅沙街道云华路 9 号华大时空中心 C 区国际会议中心 419 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 153 | | --- | --- | | 普通股股东人数 | 153 | | 2、出席会议的股东所持有的表决权数量 | 228,806,003 | | 普通股股东所持有表决权数量 | 228,806,003 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 55.4643 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比 ...

Core Viewpoint - The biopharmaceutical sector in China is experiencing a positive trend in innovation and investment, with significant growth in the approval of innovative drugs and a recovery in market conditions [1][2] Industry Summary - As of September 8, 2025, the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) increased by 0.89%, with notable gains from companies such as United Imaging Healthcare (688271) up 11.48% and BGI Genomics (688114) up 9.35% [1] - The "National Drug Safety Publicity Week" launched on September 1 highlights the positive development of the pharmaceutical industry, with 210 innovative drugs approved in the past five years, indicating a sustained growth trend [1] - Currently, approximately 30% of the world's innovative drugs under research are from China, showcasing the country's significant role in global pharmaceutical innovation [1] Company Summary - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index as of August 29, 2025, include United Imaging Healthcare (688271), BeiGene (688235), and others, collectively accounting for 50.27% of the index [2] - The Sci-Tech Biopharmaceutical ETF (588250) closely tracks the performance of the Sci-Tech Innovation Board Biopharmaceutical Index, reflecting the overall performance of representative biopharmaceutical companies listed on the Sci-Tech Board [2]

Group 1 - The medical device sector experienced a significant upward movement on September 8, with companies such as Aojing Medical, United Imaging Medical, and Kaili Medical seeing stock increases of over 10% [1] - Other companies in the sector, including Jimin Health, BGI Genomics, Dabo Medical, and Mindray Medical, also showed positive stock performance [1]

Domestic News - A total of 40 listed companies in the A-share market will have their restricted shares unlocked next week, with a combined market value of approximately 966.01 billion yuan. The companies with the highest unlock values include Times Electric (278.23 billion yuan), Southern Power Storage (230.81 billion yuan), and BGI Genomics (133.82 billion yuan) [1] - The unlock ratios for several companies exceed 50%, with Minshida at 66.23%, Southern Power Storage at 65.3%, Sailun Biotech at 59%, and Zhejiang Hengwei at 50.95% [1] International News - The 24th Economic Ministers' Meeting of the Shanghai Cooperation Organization (SCO) was held in Vladivostok, Russia, focusing on sustainable economic growth measures and planning for future regional economic cooperation [2] - The price of domestic gold jewelry has surpassed 1,060 yuan per gram, with brands like Chow Sang Sang and Lao Miao reporting increases in their gold prices [3] - The completion of the first main tower of the Zhuhai Bridge, which connects Zhoushan's Liuhong Island and Foduo Island, marks a significant milestone in infrastructure development, with a main span of 1,768 meters [3]